

Rijken DC, Lijnen HR: New insights into the molecular mechanisms of the fibrinolytic system. *J Thromb Haemost* 7:4, 2009. [Review of fibrinolytic pathways.]

### Thrombosis and Thromboembolism

Castoldi E, Rosing J: APC resistance: biological basis and acquired influences. *J Thromb Haemost* 8:445–53, 2010. [Reviews the multifactorial etiology of activated protein C resistance (e.g., factor V Leiden) and discusses its clinical implications.]

Cushman M: Epidemiology and risk factors for venous thrombosis. *Semin Hematol* 44:62, 2007. [Overview of the risk factors and pathophysiology of DVT.]

Donati MB, Lorenzet R: Thrombosis and cancer: 40 years of research. *Thromb Res* 129:348–52, 2012. [A historical perspective on questions pertaining to cancer and thrombosis stretching from the era of Trousseau to the present.]

Esmon CT, Esmon NL: The link between vascular features and thrombosis. *Annu Rev Physiol* 2011. [Review of the interactions of endothelium, blood flow, and hemostasis/thrombosis.]

Goldhaber SZ, Bounameaux H: Pulmonary embolism and deep vein thrombosis. *Lancet* 379:1835–46, 2012. [A guide to the recognition and therapy of pulmonary embolism and DVT.]

Hannaford PC: Epidemiology of the contraceptive pill and venous thromboembolism. *Thromb Res* 127(Suppl 3):S30–4, 2011. [Discussion of risk for DVT in women using various forms of hormonal contraception.]

Holy EW, Tanner FC: Tissue factor in cardiovascular disease pathophysiology and pharmacological intervention. *Adv Pharmacol* 59:259, 2010. [Review of the roles of tissue factor in hemostasis and possible strategies to prevent thrombosis.]

Hong MS, Amanullah AM: Heparin-induced thrombocytopenia: a practical review. *Rev Cardiovasc Med* 11:13, 2010. [Review of HIT mechanisms and therapies.]

Jennings LK: Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. *Thromb Haemost* 102:248, 2009. [Review of the roles played by platelets in thrombosis and inflammation, with an eye towards therapeutic intervention.]

Kelton JG, Arnold DM, Bates SM: Nonheparin anticoagulants for heparin-induced thrombocytopenia. *N Engl J Med* 368:737, 2013. [Discussion of heparin-induced thrombocytopenia and management of affected patients with non-heparin anticoagulants.]

Montagnana M, Franchi M, Danese E, et al: Disseminated intravascular coagulation in obstetric and gynecologic disorders. *Semin Thromb Hemost* 36:404, 2010. [Review of the mechanisms of DIC in the setting of pregnancy and gynecologic conditions.]

Osinbowale O, Ali L, Chi YW: Venous thromboembolism: a clinical review. *Postgrad Med* 122:54, 2010. [Basic review at a medical student/house officer level.]

Ruiz-Irastorza G, Crowther M, Branch W, et al: Antiphospholipid syndrome. *Lancet* 376:1498, 2010. [Summary of the anti-phospholipid syndrome that emphasizes diagnosis and therapy.]

Watson HG, Baglin TP: Guidelines on travel-related venous thrombosis. *Br J Haematol* 152:31–4, 2011. [Epidemiology of travel-related DVT and clinical recommendations.]

Willis R, Harris EN, Pierangeli SS: Pathogenesis of the antiphospholipid syndrome. *Semin Thromb Hemost* 38:305–21, 2012. [Highlights possible mechanisms that contribute to the development and to the action of pathogenic anti-phospholipid antibodies.]

Wu KK, Matijevic-Aleksic N: Molecular aspects of thrombosis and antithrombotic drugs. *Crit Rev Clin Lab Sci* 42:249, 2005. [Thorough overview of the mechanisms of thrombus formation.]

Zwicker J, Furie BC, Furie B: Cancer-associated thrombosis. *Crit Rev Oncol Hematol* 62:126, 2007. [Review of the mechanisms underlying the hypercoagulable state of malignancy.]

### Unusual Forms of Embolic Disease

Akhtar S: Fat embolism. *Anesthesiol Clin* 27:533, 2009. [Overview of the pathogenesis and clinical features of fat embolism syndrome.]

Benson MD: Current concepts of immunology and diagnosis in amniotic fluid embolism. *Clin Dev Immunol* 2012:946576, 2012. [Discussion of the pathophysiology of amniotic fluid embolism.]

### Septic Shock

Brosnahan AJ, Schlievert PM: Gram-positive bacterial superantigen outside-in signaling causes toxic shock syndrome. *FEBS J* 278:4649–67, 2011. [A review of molecular mechanisms of toxic shock induced by bacterial components that act as superantigens.]

Hotchkiss R, Karl I: The pathophysiology and treatment of sepsis. *N Engl J Med* 348:138, 2003. [An older paper that lays a solid pathogenic foundation for understanding sepsis.]

Lee WL, Slutsky AS: Sepsis and endothelial permeability. *N Engl J Med* 363:689–91, 2010. [A brief review of the role of endothelial leakiness in the pathogenesis of sepsis.]

Munford RS: Severe sepsis and septic shock: the role of gram-negative bacteremia. *Annu Rev Pathol* 1:467, 2006. [A review of the role of gram-negative bacteria in septic shock.]

Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, et al: The pathogenesis of sepsis. *Ann Rev Pathol Mech Dis* 6:19, 2011. [Update on approaches to understanding and treating sepsis.]